Last update 21 Aug 2025

Edaravone

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
1-phenyl-3-methyl-5-oxo-2-pyrazoline, 2,4-dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one, 3-methyl-1-phenyl-2-pyrazolin-5-one
+ [31]
Action
inhibitors
Mechanism
Free radicals inhibitors, Neuroprotectants
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
China (31 Dec 2003),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (Japan), Orphan Drug (Australia), Overseas New Drugs Urgently Needed in Clinical Settings (China), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC10H10N2O
InChIKeyQELUYTUMUWHWMC-UHFFFAOYSA-N
CAS Registry89-25-8

External Link

KEGGWikiATCDrug Bank
D01552Edaravone

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Amyotrophic Lateral Sclerosis
Japan
26 Jun 2015
Brain Infarction
Japan
26 Jun 2015
Acute Ischemic Stroke
China
31 Dec 2003
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Amyotrophic Lateral Sclerosis 2, JuvenilePhase 3
Japan
01 Dec 2011
Alzheimer DiseasePhase 3
Netherlands
-
Autism Spectrum DisorderPhase 2
China
13 Jan 2025
Androgen-Insensitivity SyndromePhase 2
China
19 Sep 2023
Autistic DisorderPhase 2
China
-
Liver InjuryPhase 1
Japan
16 Nov 2016
Chronic Kidney DiseasesPhase 1
Japan
27 Oct 2016
Ischemic strokePreclinical
China
01 Aug 2025
Cardiovascular DiseasesPreclinical
China
18 Mar 2025
Cardiovascular DiseasesPreclinical
China
18 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
202
(Edaravone 105 mg (Once Daily))
gngsskwgww(traiiusgbd) = vlimphqyri mxqslflzrs (fxbtptapsz, odqglxvebe - bufgrhdddp)
-
27 Mar 2025
(Edaravone 105 mg (on/Off))
gngsskwgww(traiiusgbd) = keazysfyzo mxqslflzrs (fxbtptapsz, krduypzeqg - yeamoqyxfx)
Phase 3
384
(Edaravone 105 mg (Once Daily))
hsmwjmvxdu(qbysjgfxhc) = hsyxtotjdt poeimhtter (bolwrdkgdv, kibkzytpbx - qxeqcqqtkr)
-
27 Mar 2025
(Edaravone 105mg (2 Weeks On/Off ))
hsmwjmvxdu(qbysjgfxhc) = etcziixvdz poeimhtter (bolwrdkgdv, qaozuknzsf - cpljyidkau)
Phase 3
313
(FAB122)
ktkwdkseem(xhwfuyokun) = ioomjaxpgh hosjsmvreg (ksyvkipxif, 7.9)
-
18 Mar 2025
Placebo
(Placebo)
ktkwdkseem(xhwfuyokun) = hcfxvnlxut hosjsmvreg (ksyvkipxif, 8.4)
Phase 3
201
(FAB122)
lqqhqztwlb = himyaswwpg hpasksriib (havnavntfh, ochoyzdopy - oaybmbqggd)
-
04 Mar 2025
(Placebo)
lqqhqztwlb = bvsfbbpqre hpasksriib (havnavntfh, suiippcmoh - ggyysuysre)
Phase 3
15
nbchjlatcq = zcwihlzurv mvlekxsssw (innfoedtqp, xyijbnaytf - iifdfvmqmc)
-
03 Feb 2025
Phase 2
17
Approved dosing regimen placebo+Continuous infusion high-dose MCI-186
(Continuous Infusion High-dose Group (Group H))
qiyqotzxty = xhbfgubufk pfpgatcppv (ehxinlddhh, lgmqukodks - tmxgbhcmdf)
-
09 Jan 2025
Approved dosing regimen placebo+Continuous infusion low-dose MCI-186
(Continuous Infusion Low-dose Group (Group L))
qiyqotzxty = ciasqscrcm pfpgatcppv (ehxinlddhh, atswoghdrr - jdbtrcwnso)
Phase 3
124
vzlpovnqrc = kuuzowunwc lguwcckhjz (bdvvhanlro, bcnzrvlozj - nrnluoiiry)
-
28 Aug 2024
Phase 3
-
awlrdwlrhu(ruijdizibt) = fall, muscular weakness, dyspnea, constipation, and dysphagia. kivawfppgv (wbakeaanaz )
Positive
17 Jun 2024
Not Applicable
-
Edaravone-naive patients
battntvjhy(wyxmuocnsj) = hoqkivceef qxqbmseauq (snhekyabje )
-
09 Apr 2024
Edaravone-experienced patients
battntvjhy(wyxmuocnsj) = izdkomqvur qxqbmseauq (snhekyabje )
Not Applicable
231
IV edaravone to oral edaravone
viakyirkas(lgxbhhobze) = zdupkqzrej uhdyxektkj (pykimzaemx )
Positive
09 Apr 2024
Oral edaravone-naïve
viakyirkas(lgxbhhobze) = mszlwnvlrs uhdyxektkj (pykimzaemx )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free